患者开始使用他类药物治疗的短期和长期他类药物持续性和决定因素
Mehmet Uzunlulu1, Cundullah Torun1, Erhan Eken1
1Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcın City Hospital, Department of Internal Medicine, Istanbul, Türkiye.
Medeniyet medical journal
|September 29, 2025
概括
立方体持续率很低,并且正在下降,特别是在年轻的患者和接受初级预防的患者中. 对于患有高血压,糖尿病和冠状动脉疾病等现有心血管疾病的患者,持久性更高.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 类药物对于减少心血管事件和死亡率至关重要.
- 低的他类药物持续性率是心血管疾病管理的一个重大挑战.
研究的目的:
- 为了评估短期和长期的他类药物持久率.
- 为了确定影响新使用者的他类药物持续性的因素.
主要方法:
- 对903名开始使用他类药物治疗的患者进行了回顾性观察性研究 (2016-2017年).
- 评估了2018年 (短期) 和2023年 (长期) 的他类药物持久性.
- 在持久性和非持久性组之间比较人口,临床和治疗特征.
主要成果:
- 短期持久性 (2018年) 为55.1%;长期持久性 (2023年) 为51.7%.
- 在45岁以下的患者和接受初级预防的患者中,非持续性更高 (p<0.01).
- 患有高血压,糖尿病和冠状动脉疾病的患者的持续性更高 (所有p<0.01).
结论:
- 达丁类药物持久性率较低,并且随着时间的推移而下降.
- 年轻的患者和接受初级预防的患者表现出较低的他类药物持久性.
- 患有高血压,糖尿病和CAD等并发症的存在与更高的他类药物持续性有关.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
219
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
219
Factors Affecting Protein-Drug Binding: Patient-Related Factors
305
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
305
Steady State Concentration
5.8K
A steady state refers to the level of a drug in the body once it has reached an equilibrium between administration and elimination. It represents the point at which the drug administration rate equals the drug elimination rate, resulting in a relatively constant concentration in the body over time. The dynamic equilibrium is crucial to ensure the drug's effectiveness with minimal risk of toxicity.
Most drugs are administered in repeated doses at fixed intervals or through continuous...
Most drugs are administered in repeated doses at fixed intervals or through continuous...
5.8K
Drug Product Stability
226
The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
226


